Clifford Siegel, Former Jefferies International CEO and Stifel Nicolaus Europe Vice-Chairman Joins Bryan, Garnier & Co as Non-Executive Chairman
12.1.2021 11:00:00 EET | Business Wire | Press release
Bryan, Garnier & Co, a leading pan-European Investment Bank focusing on growth companies, is delighted to announce that Clifford Siegel has been appointed as Non-Executive Chairman at the firm.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210112005055/en/
Clifford Siegel, former Jefferies International CEO and Stifel Nicolaus Europe Vice-Chairman joins Bryan, Garnier & Co as Non-Executive Chairman (Photo: Bryan, Garnier & Co)
Based in London, Clifford will take up this new position to help develop Bryan, Garnier & Co’s strategy across Europe and the US.
Clifford, 63, has a distinguished career in the investment banking industry. After starting and running the US business of the Cresvale Group, he joined Jefferies in New York in 1990, before moving to London in 1993 to become the CEO of the group’s international business.
During Clifford’s 18-year tenure, Jefferies International grew from a small team in London to a global business with revenues of over USD 300m and offices in Asia and Europe. After retiring from Jefferies, he later founded and ran the debt capital markets boutique ISM Capital, before selling the business to Stifel Nicolaus Europe in 2016. He retired from his role as Vice-Chairman of Stifel Nicolaus Europe Ltd in the autumn of 2020.
Olivier Garnier, Co-founder & Managing Partner states: “We are delighted to welcome Cliff to Bryan, Garnier & Co. He brings both a wealth of experience in all facets of the banking business that will help us expand our business footprint and support our strategic ambitions”.
Clifford Siegel comments: “I have admired the remarkable success and consistency of Bryan, Garnier & Co for many years. I am delighted to be joining them at a time when, now more than even, there is a need for highly committed investment bankers with outstanding quality standards, deep industry expertise and broad transaction capacities to support growth companies and their shareholders”.
In his capacity, Clifford will contribute to strengthening the group’s corporate development initiatives. This includes strategic acquisitions and alliances following Bryan, Garnier & Co’s recent developments in the Nordics and the US, as well as the expansion of the firm’s activities in complementary areas such as fixed income and debt advisory.
With more than 60 private and public capital-raising and M&A transactions closed in 2020, Bryan, Garnier & Co benefits from its longstanding leadership in the healthcare, technology and environmental sectors in Europe. Recent transactions include the sale of smartTrade to leading software private equity investor Hg Capital, the take-private of ITSM player Easyvista by Eurazeo, capital for circular economy player asgoodasnew, the sale of Specim to Konica Minolta and the sale of BlueBee to Illumina. Over the years, Bryan, Garnier & Co has distinguished itself by backing some of the most disruptive companies in the domain of alternative proteins (Prolupin), green hydrogen (McPhy Energy), cannabis (Canopy Growth), blockchain and cryptocurrencies (Bitfury Group), and mRNA biotech (Moderna and BioNTech).
About Bryan, Garnier & Co (www.bryangarnier.com)
Bryan, Garnier & Co is a European, full-service growth-focused independent investment banking partnership founded in 1996. The firm provides equity research, sales and trading, private and public capital raising as well as M&A services to growth companies and their investors. It focuses on key growth sectors of the economy including Technology, Healthcare, Consumer and Business Services. Bryan, Garnier & Co is a fully registered broker dealer authorized and regulated by the FCA in the UK, the AMF in Europe and the FINRA in the U.S. Bryan, Garnier & Co is headquartered in London, with additional offices in Paris, Munich, Stockholm, Oslo, Reykjavik as well as New York and Palo Alto.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112005055/en/
Contact information
Press contact: Profile!
Margaux Frantz / Leslie BOUTIN- SOSSAH
+ 33-1-56-26-72-32 / 33
mfrantz@agence-profile.com
lboutin@agence-profile.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 16:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 16:00:00 EEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 15:48:00 EEST | Press release
Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong engagement across asset classes, geographies and user activity: Users from more than 180 different countries $38.4 billion in cumul
Klarna Submits Application for U.S. Banking License6.7.2026 15:30:00 EEST | Press release
Klarna (NYSE: KLAR), the global digital bank and flexible payments provider, today announced it has submitted applications to the Utah Department of Financial Institutions and the Federal Deposit Insurance Corporation (FDIC) to establish Klarna Bank USA, a proposed Utah-chartered industrial bank. Klarna has operated as a licensed bank in Europe since 2017 and serves U.S. customers through valued partner banks. Since 2019, Klarna has provided Americans with access to over $91.3 billion in responsible credit, saving them more than $5.1 billion in interest compared to revolving credit card debt. Today, 30 million Americans use Klarna each year, and hundreds of thousands of merchants rely on Klarna to grow their businesses. "Banking is built on trust," said Sebastian Siemiatkowski, co-founder and CEO of Klarna. "We've seen firsthand the appetite for a fairer, more transparent approach in the U.S., and our own banking license is the natural next step, giving customers tools to borrow respon
IQM Quantum Computers Acquires Assets of Quantistry GmbH to Bridge the Gap Between Quantum Algorithms and Solutions for Industrial Enterprises6.7.2026 15:00:00 EEST | Press release
IQM Quantum Computers (Nasdaq: IQMX) (“IQM”, “IQM Quantum Computers” or the “Company”), a global leader in full-stack superconducting quantum computers, has acquired selected assets of Quantistry GmbH, a Berlin-based developer of cloud-native simulation workflow platform for automotive, aerospace, chemical, materials and pharmaceutical industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706448170/en/ IQM Quantum Computers Acquires Assets of Quantistry GmbH to bridge the gap between Quantum Algorithms and Solutions for Industrial Enterprises The acquired assets include proprietary software applications, algorithms, and intellectual property. IQM will also retain Quantistry's core technical, quantum chemistry, and software engineering talent, ensuring seamless continuity and rapid platform integration. The transaction completed recently, concurrently with IQM's business combination with Real Asset Acquisition Corp. (
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom